aTyr Pharma Announces Last Patient Visit in Phase 1b/2a Clinical Trial of ATYR1923 in Patients with Pulmonary Sarcoidosis
aTyr Pharma (Nasdaq: LIFE) announced that the last patient in its Phase 1b/2a clinical trial of ATYR1923 for pulmonary sarcoidosis has completed their final visit. The trial, involving 37 patients, aims to assess the safety, tolerability, and preliminary efficacy of ATYR1923. Results are anticipated in September 2021. ATYR1923, a fusion protein targeting neuropilin-2, seeks to modulate immune responses in severe inflammatory lung diseases. This milestone is a significant step for aTyr and the sarcoidosis community.
- Completion of last patient visit in Phase 1b/2a clinical trial for ATYR1923.
- Results expected in September 2021.
- ATYR1923 shows potential therapeutic benefits for pulmonary sarcoidosis.
- None.
Results from proof-of-concept study are expected in September 2021.
SAN DIEGO, July 08, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that the last patient has completed their last visit in the company’s Phase 1b/2a clinical trial of its lead therapeutic candidate, ATYR1923, in patients with pulmonary sarcoidosis, a major form of interstitial lung disease. The company expects to report results from this trial in September 2021.
“We are pleased to complete the last patient visit in this important study, which represents a significant milestone for aTyr, our ATYR1923 clinical program and the sarcoidosis community,” said Sanjay Shukla, M.D., M.S., President and Chief Executive Officer of aTyr. “We would like to thank all of the patients, investigators and the Foundation for Sarcoidosis Research for their support and efforts that helped make this possible. We look forward to sharing the results in September.”
The Phase 1b/2a study is a multiple-ascending dose, double-blind, placebo-controlled study in 37 patients with pulmonary sarcoidosis that was designed to evaluate the safety, tolerability, immunogenicity and pharmacokinetic profile of multiple doses of ATYR1923 compared to placebo, as well as to evaluate preliminary efficacy measures including steroid sparing effect, measures of lung function and potential disease biomarkers.
About ATYR1923
aTyr is developing ATYR1923 as a potential therapeutic for patients with severe inflammatory lung diseases. ATYR1923, a fusion protein comprised of the immuno-modulatory domain of histidyl-tRNA synthetase fused to the FC region of a human antibody, is a selective modulator of neuropilin-2 that downregulates the innate and adaptive immune response in inflammatory disease states. aTyr has completed enrollment in a proof-of-concept Phase 1b/2a trial evaluating ATYR1923 in patients with pulmonary sarcoidosis. This Phase 1b/2a study is a multi-ascending dose, placebo-controlled, first-in-patient study of ATYR1923 that has been designed to evaluate the safety, tolerability, steroid sparing effect, immunogenicity and pharmacokinetic profile of multiple doses of ATYR1923. Proof-of-mechanism for ATYR1923 was recently established in a Phase 2 clinical trial in COVID-19 patients with severe respiratory complications, which demonstrated that ATYR1923 reduced inflammatory cytokine levels in patients consistent with preclinical models, including cytokines that are implicated in sarcoidosis and other forms of interstitial lung disease.
About aTyr
aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways. aTyr’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyr’s primary focus is ATYR1923, a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to down-regulate immune engagement in inflammatory lung diseases. For more information, please visit http://www.atyrpharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are usually identified by the use of words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “seeks,” “should,” “will,” and variations of such words or similar expressions. We intend these forward-looking statements to be covered by such safe harbor provisions for forward-looking statements and are making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements include statements regarding potential therapeutic benefits and applications of ATYR1923; timelines and plans with respect to certain development activities (such as the timing of data from clinical trials); and certain development goals. These forward-looking statements also reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects, as reflected in or suggested by these forward-looking statements, are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. All forward-looking statements are based on estimates and assumptions by our management that, although we believe to be reasonable, are inherently uncertain. Furthermore, actual results may differ materially from those described in these forward-looking statements and will be affected by a variety of risks and factors that are beyond our control including, without limitation, uncertainty regarding the COVID-19 pandemic, risks associated with the discovery, development and regulation of our product candidates, the risk that we or our partners may cease or delay preclinical or clinical development activities for any of our existing or future product candidates for a variety of reasons (including difficulties or delays in patient enrollment in planned clinical trials), the possibility that existing collaborations could be terminated early, and the risk that we may not be able to raise the additional funding required for our business and product development plans, as well as those risks set forth in our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and in our other SEC filings. Except as required by law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
| Contact: |
| Ashlee Dunston |
| Director, Investor Relations and Corporate Communications |
| adunston@atyrpharma.com |
FAQ
What were the results of aTyr Pharma's Phase 1b/2a trial for ATYR1923?
What is the purpose of the ATYR1923 clinical trial?
How many patients participated in the ATYR1923 trial?
What is ATYR1923 designed to do?
What company is conducting the ATYR1923 clinical trial?
